An Investigation on The Clinical Characteristics of Cases with Lung Cancer in The South-eastern Anatolian Region

Year 2021, Volume: 13 Issue: 1, 11 - 17, 30.06.2021

Abdullah Karakuş , Vehbi Demircan , Abdurrahman Işıkdoğan

Abstract

Objective: The present study aimed to retrospectively determine the demographic, epidemiological, and clinical characteristics of the patients with lung cancer monitored in our clinic.
Material and Method: The study retrospectively investigated 865 patients with lung cancer diagnosed, treated, and monitored between 2000 and 2011 in the Medical Oncology
Result: Of the 865 patients with lung cancer, 691 (79.5%) had Non-small Cell Lung Cancer (NSCLC), and 174 (20.5%) had Small Cell Lung Cancer (SCLC). Of the patients with NSCLC, 12.3% were in the local stage, 34.7% in the locally advanced stage, and 53% in the metastatic stage.
The mean survival time of the patients was 31 months in the local stage, 17 months in the locally advanced group, and 9 months in the metastatic period. The smoking rates of patients were 93.8% in patients with squamous cell cancer, 72.5% in those with adenocarcinoma, and 91.4% in those with SCLC.
Conclusion: Regarding the histopathological subgroups of the patients in our study, we have observed that adenocarcinoma patients rate was higher compared with the average data observed in our country. The smoking rate in patients with adenocarcinoma was less than the average tendency in our country.

Keywords

Lung cancer, smoking, metastasis

References

• 1.Fitzmaurice C, Dicker D, Pain A, et al. The Global Burden of Cancer 2013. JAMA Oncology. 2015; 1(4): 505–527.
• 2. Jemal A, Center MM, DeSantis C and Ward EM. Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiology Biomarkers & Prevention. 2010; 19(8): 1893–1907.
• 3. Alberg AJ, Samet JM. Epidemiology of lung cancer. Chest 2003; 123:21S.
• 4. İtil O. Akciğer kanserlerinin epidemiyolojisi ve etyolojisi. In: Haydaroğlu A; ed. Akciğer kanserleri: Tanı ve tedavi. İzmir: Ege Universitesi Basımevi; 2000:15-34.
• 5. Kraut M, Wozniak A. Clinical presentation. In: Pass HI, Mitchell JB, Johnson DH et al; eds. Lung cancer principle and practice. Philadelphia: Lippincott Williams &Wilkins; 2000:521-34.
• 6.Groome PA, Bolejack V, Crowley JJ, Kennedy C, Krasnik M, Sobin LH, Goldstraw P, IASLC International Staging Committee, Cancer Research and Biostatistics, Observers to the Committee, Participating Institutions. The IASLC Lung Cancer Staging Project: validation of the proposals for revision of the T, N, and M descriptors and consequent stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol. 2007;2:694
• 7. Travis WD. Pathology of lung cancer. Clinics in ChestMedicine. 2011; 32(4):669-92.
• 8. Wells CK, Peduzzi PN, Feinstein AR. Presenting manifestations, cigarette smoking, and detection bias in age at diagnosis of lung cancer; Ann Epidemiol. 2001 May;11(4):239-47.
• 9. Lung and Pleural Malignancies Study Group. Pattern of lung cancer in Turkey 1994-1998. Turkish Thoracic Society. Respiration 2002;69:207-210.
• 10.Göksel T, Eser S. Türkiye’nin akciğer kanseri insidansı. Türk ToraksDerneği 13. Yıllık Kongresi; 05-09 Mayıs 2010, İstanbul.
• 11.Anthony J. Alberg, PhD, MPH; and Jonathan M. Samet, MD, MS Epidemiology of Lung Cancer; Chest 2003;123;21S-4
• 12 Xing P-Y, Zhu Y-X, Wang L, et al. . What are the clinical symptoms and physical signs for non-small cell lung cancer before diagnosis is made? A nation-wide multicenter 10-year retrospective study in China. Cancer Med 2019;8:4055-69.
• 13. Jackman DM, Johnson BE. Small-cell lung cancer. Lancet 2005;366(9494):1385-96.
• 14. Spiro SG, Porter JC: Lung cancer-Where are we today? Current advances in staging and nonsurgical treatment. Am J Respir Crit Care Med 2002;166:1166-96.